You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

McKinsey
Moodys
Dow
Baxter
Harvard Business School
Mallinckrodt

Last Updated: December 7, 2023

Eravacycline dihydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for eravacycline dihydrochloride and what is the scope of patent protection?

Eravacycline dihydrochloride is the generic ingredient in one branded drug marketed by Tetraphase Pharms and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eravacycline dihydrochloride has eighty patent family members in thirty-three countries.

One supplier is listed for this compound.

Summary for eravacycline dihydrochloride
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for eravacycline dihydrochloride
Generic Entry Date for eravacycline dihydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for eravacycline dihydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
West Virginia UniversityPhase 2
Tetraphase Pharmaceuticals, Inc.Phase 3
Tetraphase Pharmaceuticals, Inc.Phase 1

See all eravacycline dihydrochloride clinical trials

Pharmacology for eravacycline dihydrochloride

US Patents and Regulatory Information for eravacycline dihydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-002 Jun 3, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-002 Jun 3, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-002 Jun 3, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-002 Jun 3, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-001 Aug 27, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Tetraphase Pharms XERAVA eravacycline dihydrochloride POWDER;INTRAVENOUS 211109-002 Jun 3, 2020 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for eravacycline dihydrochloride

Country Patent Number Title Estimated Expiration
Taiwan 201016646 C7-fluoro substituted tetracycline compounds ⤷  Try a Trial
Netherlands 300971 ⤷  Try a Trial
Hong Kong 1222840 -氟取代的四環素化合物 (C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS C7-) ⤷  Try a Trial
Croatia P20130928 ⤷  Try a Trial
Hong Kong 1193412 -氟取代的四環素化合物 (C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS C7-) ⤷  Try a Trial
Croatia P20151368 ⤷  Try a Trial
Israel 211120 תרכובת, טטראציקלין מותמרת בעמדה 7c עם פלואור, תכשיר רוקחות המכיל אותה ושימוש בה להכנת תרופות לטיפול בזיהום הנגרם על ידי בקטריה (C7-fluoro substituted tetracycline compound, pharmaceutical composition comprising it and its use in the manufacture of medicaments for treating infection caused by bacteria) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for eravacycline dihydrochloride

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2323972 19C1012 France ⤷  Try a Trial PRODUCT NAME: ERAVACYCLINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/18/1312 20180924
2323972 C20190009 00277 Estonia ⤷  Try a Trial PRODUCT NAME: ERAVATSUEKLIIN;REG NO/DATE: EU/1/18/1312 24.09.2018
2323972 PA2019009,C2323972 Lithuania ⤷  Try a Trial PRODUCT NAME: ERAVACIKLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1312 C(2018)6231 20180920
2323972 CR 2019 00009 Denmark ⤷  Try a Trial PRODUCT NAME: ERAVACYCLIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1312 20180209
2323972 300971 Netherlands ⤷  Try a Trial PRODUCT NAME: ERAVACYCLINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/18/1312 20180924
2323972 2019C/511 Belgium ⤷  Try a Trial PRODUCT NAME: ERAVACYCLINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1312 20180924
2323972 1990014-1 Sweden ⤷  Try a Trial PRODUCT NAME: ERAVACYCLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/18/1312 20180924
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Harvard Business School
McKinsey
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.